In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 11, 1997, Pages 2573-2575

  Mercier, Renee Claude ^a,d   Penzak, Scott R ^a   Rybak, Michael J ^a,b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; CL 331002; CLINAFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; EPEREZOLID; GENTAMICIN; GLYCOPEPTIDE; OFLOXACIN; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN; STREPTOMYCIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0030671391     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.11.2573     Document Type: Article

References (22)

1. Arthur, M., and P. Courvalin. 1993. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. 37:1563-1571.
2. Bostic, G., M. B. Perri, L. A. Thal, and M. J. Zervos. 1995. Comparative in-vitro and bactericidal activity of oxazolidinone antibiotics against multidrug resistant enterococci, abstr. F219, p. 151. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Burney, S., D. Landman, and J. M. Quale. 1994. Activity of clinafloxacin against multidrug-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 38:1668-1670.
4. Bush, L. M., J. Calmon, C. L. Cherney, M. Wendeler, P. Pitsakis, J. Poupard, M. E. Levison, and C. C. Johnson. 1989. High-level penicillin resistance among isolates of enterococci. Ann. Intern. Med. 110:515-520.
5. Cappelletty, D. M., R. C. Mercier, and M. J. Rybak. 1995. In vitro activity of CL 331,002, a new glycylcycline (GL) compound against Staphylococcus aureus and Enterococcus faecium, abstr. F14, p. 115. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Caron, F., M. Pestel, M. D. Kitzis, J. F. Lemeland, G. Humbert, and L. Gutmann. 1995. Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium. J. Infect. Dis. 171:106-112.
7. Eliopoulos, G. M., and R. C. Moellering. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
8. Emori, T. G., and R. P. Gaynes. 1993. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin. Microbiol. Rev. 6:428-442.
9. Fraise, A. P., N. Brenwald, J. M. Andrews, and R. Wise. 1995. In-vitro activity of two glycylcyclines against enterococci resistant to other agents. J. Antimicrob. Chemother. 35:877-881.
10. Hunter, T. H. 1947. Use of streptomycin in the treatment of bacterial endocarditis. Am. J. Med. 2:436-442.
11. Kaatz, G. W., S. M. Seo, K. C. Lamp, E. M. Bailey, and M. J. Rybak. 1992. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 36:1192-1197.
12. Kang, S. L., and M. J. Rybak. 1995. Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and staphylococcus-infected fibrin clots. Antimicrob. Agents Chemother. 39:2832-2834.
13. Moellering, R. C. 1991. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J. Antimicrob. Chemother. 28:1-12.
14. Morbidity and Mortality Weekly Report. 1993. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. Morbid. Mortal. Weekly Rep. 42:597-599.
15. Nachamkin, I., P. Axelrod, G. H. Talbot, S. H. Fischer, C. B. Wennersten, R. C. Moellering, and R. R. MacGregor. 1988. Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital. J. Clin. Microbiol. 26:1287-1291.
16. National Committee for Clinical Laboratory Standards. 1994. Approved standard. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS document M7-A. National Committee for Laboratory Standards, Villanova, Pa.
17. Norrby, S. R., and M. Jonsson. 1988. Comparative in vitro activity of PD 127391, a new fluorinated 4-quinolone derivative. Antimicrob. Agents Chemother. 32:1278-1281.
18. Quale, J. M., N. K. Mobarakai, and D. Landman. 1993. Treatment of experimental endocarditis caused by multi-drug resistant Enterococcus faecium with ampiculin and ciprofloxacin, abstr. 109. In Program and abstracts of the 31st Annual Meeting of Infectious Diseases Society of America. University of Chicago Press, Chicago, Ill.
19. Quintiliani, R., S. Evers, and P. Courvalin. 1993. The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J. Infect. Dis. 167:1220-1223.
20. Shlaes, D. M., A. Bouvet, C. Devine, H. Shlaes, S. Al-Obeid, and R. Williamson. 1989. Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256. Antimicrob. Agents Chemother. 33:198-203.
21. Tack, K. J., N. M. McGuire, and I. A. Eiseman. 1995. Initial clinical experience with clinafloxacin in the treatment of serious infections. Drugs 49: 488-491.
22. Zeckel, M. Personal communication.